BE607336A - - Google Patents
Info
- Publication number
- BE607336A BE607336A BE607336DA BE607336A BE 607336 A BE607336 A BE 607336A BE 607336D A BE607336D A BE 607336DA BE 607336 A BE607336 A BE 607336A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- amine
- amines
- salt
- salts
- Prior art date
Links
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 claims description 322
- 239000000203 mixture Substances 0.000 claims description 47
- 150000001412 amines Chemical class 0.000 claims description 43
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 26
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 15
- 230000000507 anthelmentic Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 11
- NAPSCFZYZVSQHF-UHFFFAOYSA-N N,N-dimethyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- MNOIOAHRVYPSPE-UHFFFAOYSA-N N,N-diethyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(CC)CC MNOIOAHRVYPSPE-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- YWMZGHAFYBXDIQ-UHFFFAOYSA-N N-ethyl-N-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC YWMZGHAFYBXDIQ-UHFFFAOYSA-N 0.000 claims description 4
- SZEGKVHRCLBFKJ-UHFFFAOYSA-N N-methyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNC SZEGKVHRCLBFKJ-UHFFFAOYSA-N 0.000 claims description 4
- -1 amine salt Chemical class 0.000 claims description 4
- YIADEKZPUNJEJT-UHFFFAOYSA-N N-ethyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCC YIADEKZPUNJEJT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 3
- 230000004083 survival Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 20
- 206010061217 Infestation Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 241000244206 Nematoda Species 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 230000002354 daily Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 241000242722 Cestoda Species 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 241000242594 Platyhelminthes Species 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000921 anthelmintic agent Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000222920 Hedeoma nana Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 241000243780 Heligmosomoides polygyrus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- MHZGKXUYDGKKIU-UHFFFAOYSA-N decan-1-amine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 4
- MHZGKXUYDGKKIU-UHFFFAOYSA-O decylazanium Chemical compound CCCCCCCCCC[NH3+] MHZGKXUYDGKKIU-UHFFFAOYSA-O 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000045947 parasites Species 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PLZVEHJLHYMBBY-UHFFFAOYSA-O tetradecylazanium Chemical compound CCCCCCCCCCCCCC[NH3+] PLZVEHJLHYMBBY-UHFFFAOYSA-O 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 210000003608 Feces Anatomy 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 241000975692 Syphacia obvelata Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000003203 everyday Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000020374 simple syrup Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 229940036592 ANTHELMINTICS Drugs 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N Arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 208000006968 Helminthiasis Diseases 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 229940058905 Antimony compounds for treatment of leishmaniasis and trypanosomiasis Drugs 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 240000005368 Areca catechu Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 210000004534 Cecum Anatomy 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014881 Enterobiasis Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N Hexylresorcinol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 229960003258 Hexylresorcinol Drugs 0.000 description 1
- 241000404582 Hymenolepis <angiosperm> Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- GMHOBBMCBIWTKO-UHFFFAOYSA-N [Cl-].C[NH+](CCCCCCCCCCCCCCCCCC)CC Chemical compound [Cl-].C[NH+](CCCCCCCCCCCCCCCCCC)CC GMHOBBMCBIWTKO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001463 antimony compounds Chemical class 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000001729 chan in Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- OWLCGQZKRYSCIZ-UHFFFAOYSA-N diethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](CC)CC OWLCGQZKRYSCIZ-UHFFFAOYSA-N 0.000 description 1
- PFKRTWCFCOUBHS-UHFFFAOYSA-N dimethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)C PFKRTWCFCOUBHS-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecan-1-amine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N hexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-O hexadecylazanium Chemical compound CCCCCCCCCCCCCCCC[NH3+] FJLUATLTXUNBOT-UHFFFAOYSA-O 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- YHIXOVNFGQWPFW-UHFFFAOYSA-N octadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH3+] YHIXOVNFGQWPFW-UHFFFAOYSA-N 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 201000001181 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N tetradecan-1-amine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229930007823 thymol Natural products 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE607336A true BE607336A (pt) |
Family
ID=192931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE607336D BE607336A (pt) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE607336A (pt) |
-
0
- BE BE607336D patent/BE607336A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070196472A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| BE1015217A5 (pt) | ||
| FR2613619A1 (fr) | Medicaments, produits dietetiques ou produits d'hygiene sous forme de compositions pulverulentes obtenues par adsorption de principes actifs sur un sucre a dissolution rapide | |
| FR2590170A1 (fr) | Agents therapeutiques a base de sel d'acyloxyalcanoylcholine, apportant une amelioration dans le traitement de la demence | |
| CH634055A5 (fr) | Sel d'aluminium soufre, son procede de preparation et compositions cosmetiques et pharmaceutiques le contenant. | |
| FR2904774A1 (fr) | Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent. | |
| EP2165704A1 (fr) | Utilisation de l'alvérine dans le traitement des affections cutanées | |
| FR2584405A1 (fr) | Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation | |
| US4020159A (en) | Methods of and medications for treating cardiac disorders by using strophanthin | |
| BE607336A (pt) | ||
| DE2348577C2 (de) | 1-Amino-4-phenyl-1,2,3,4-tetrahydronaphthaline, deren pharmakologisch verträglichen Salze und diese enthaltende pharmazeutische Zubereitungen | |
| FR2467596A1 (fr) | Compositions pharmaceutiques de tiaramide ou de son sel et d'un agent reglant la dissolution, a longue duree d'action | |
| WO2003086356A1 (en) | Diphenhydramine tannate solid dose compositions and methods of use | |
| US4303659A (en) | Schistosomicidal compositions | |
| BE1003959A5 (fr) | Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale. | |
| EP0280290B1 (de) | Mittel mit antidepressiver Wirkung | |
| FR2547730A1 (fr) | Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie | |
| JPH06507917A (ja) | 抗真菌剤 | |
| IL44357A (en) | Anthelmintic composition containing 2-benzoyl-4-oxo-1,2,3,6,7,11b-hexahydro-4h-pyrazino (2,1-a) isoquinoline | |
| BE897756A (fr) | Compositions pharmaceutiques a base de benzodiazepine, leur preparation et leur utilisation | |
| FR2460671A1 (fr) | Nouvelles compositions pharmaceutiques a base d'un derive de l'indole et d'une benzodiazepine | |
| FR2595048A1 (fr) | Composition pharmaceutique a base d'un derive de pyrimidine et ses applications therapeutiques | |
| BE568046A (pt) | ||
| BE856652A (fr) | Composition pharmaceutique pour le traitement des troubles du sommeil |